The Confirmatory Olmesartan Plaque Regression Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 114 participants.
Also called NCT01132768
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 114 participants
- Registry
-
NCT01132768
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Terminated
Technical summary
Registry record NCT01132768. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Confirmatory Olmesartan Plaque Regression Study
- Acronym
- CONFIRM
- Condition
- Essential Hypertension
- Condition
- Carotid Plaque
- Intervention (Drug)
- Atenolol
- Intervention (Drug)
- olmesartan medoxomil
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Record details
- Record id
cardio:ct-nct01132768- Content hash
967e65d9bcdff5493f2b5ca646ba0f60b7592234b02eeb4b44883ea81cb03289